Omair Saleh
056c47581f
Ships the second dashboard surface — a Pattern Library + Preview Theatre — that presents the 4-section PDP pilot batch back to Umar, compliance, and the board in an editorial format. Adds the full data layer that drives it: 5 source-backed per-SKU drafts at QA 100/100, 15 competitor PDP semantic extracts, PubMed evidence packs, EFSA claims library extension, JV brand voice guide, hand-curated product FAQs, and the Matrixify-ready CSV exports for Lewis. Co-Authored-By: Claude Opus 4.7 (1M context) <noreply@anthropic.com>
31 lines
1.1 KiB
JSON
31 lines
1.1 KiB
JSON
{
|
|
"sku": "JV-VISISOFT",
|
|
"name": "Visisoft Original Tablets - 10mg",
|
|
"generatedAt": "2026-05-20T03:21:07.100Z",
|
|
"generatedBy": "generate-top3-internet-evidence.ts",
|
|
"coverage": "top3_public_internet_evidence",
|
|
"blockers": [
|
|
{
|
|
"rank": 1,
|
|
"blocker": "Hard-to-prove effect",
|
|
"evidence": "Public reviews explicitly say effects can be hard to prove.",
|
|
"fix": "Expectation management and balanced FAQ.",
|
|
"confidence": "medium_public_snippet"
|
|
},
|
|
{
|
|
"rank": 50,
|
|
"blocker": "Cross-product contamination risk",
|
|
"evidence": "Frequently-bought-together products on the page are excluded from Visisoft product claims.",
|
|
"fix": "Exclude this language from final product copy and source extraction.",
|
|
"confidence": "high"
|
|
},
|
|
{
|
|
"rank": 51,
|
|
"blocker": "Cross-product contamination risk",
|
|
"evidence": "Medical-condition review language such as AMD/glaucoma is not converted into treatment claims.",
|
|
"fix": "Exclude this language from final product copy and source extraction.",
|
|
"confidence": "high"
|
|
}
|
|
]
|
|
}
|